Why the study?
Risk scores may identify patients with mitral regurgitation at risk for adverse events who may still benefit from TEER, prompting cross-validation of the MitraScore and COAPT risk score.
Do the MitraScore and COAPT risk scores accurately predict mortality in patients with mitral regurgitation undergoing or eligible for transcatheter edge-to-edge repair?
Do the MitraScore and COAPT risk scores accurately predict mortality in patients with mitral regurgitation undergoing or eligible for transcatheter edge-to-edge repair?
Both the MitraScore and COAPT risk score are simple, validated tools that provide fair to good predictive accuracy for 2-year mortality in patients undergoing transcatheter edge-to-edge repair for mitral regurgitation.
Background: Risk scores may identify patients with mitral regurgitation (MR) who are at risk for adverse events, but who may still benefit from transcatheter edge-to-edge repair (TEER). We sought to cross-validate the MitraScore and COAPT risk score to predict adverse events in patients undergoing TEER. Methods: MitraScore validation was carried out in the COAPT population which included 614 patients with FMR who were randomized 1:1 to guideline-directed medical therapy (GDMT) with or without TEER and were followed for 2 years. Validation of the COAPT risk score was carried out in 1007 patients from the MIVNUT registry of TEER-treated patients with both FMR and degenerative MR who were followed for a mean of 2.1 years. The predictive value was assessed using the area under the receiver operating characteristic curve (AUC) plots. The primary outcome was all-cause mortality. Results: The MitraScore had fair to good predictive accuracy for mortality in the overall COAPT trial population (AUC, 0.67); its accuracy was higher in patients treated with TEER (AUC, 0.74) than GDMT alone (AUC, 0.65). The COAPT risk score had fair predictive accuracy for death in the overall MitraScore cohort (AUC, 0.64), which was similar in patients with FMR and degenerative MR (AUC, 0.64 and 0.66, respectively). There was a consistent benefit of treatment with TEER plus GDMT compared with GDMT alone in the COAPT trial population across all MitraScore risk strata. Conclusions: The COAPT risk score and MitraScore are simple tools that are useful for the prediction of 2-year mortality in patients eligible for or undergoing treatment with TEER.
No takes yet. Share an insight, caveat, or question.
Estévez‐Loureiro et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: